title: [Sepsis with Staphylococcus aureus in immunocompromised patients].
abstract: The aim of our study was to analyze clinical and biological characteristics of immunocompromised patients with staphylococcal sepsis and to compare with the same data in non-immunocompromised patients.
  
  
  METHODS
  The diagnosis of sepsis was made based on Bone criteria. MiniAPI system ID 32 STAPH was used for identification and antibiotic susceptibility was assessed by ATB STAPH method and by E-test for oxacillin and vancomycin.
  
  
  RESULTS
  Among the 147 patients with Staphylococcus aureus sepsis--66.67% had concomitant immunosuppressive conditions (diabetes mellitus, liver diseases, renal failure, corticotherapy, etc). We have found a significant correlation between the immunosuppressed status and MRSA (methicillin-resistant Staphylococcus aureus) involvement (p = 0.0018) and also, between this group of patients and treatment failure (p = 0.0012).
  
  
  CONCLUSIONS
  Because of the high rate of MRSA involvement in systemic infections in the Eastern region of Romania first intention treatment of patients with staphylococcal infections and conditions of immunosuppression must include antibiotics effective against methicillin-resistant strains.
authors.affiliation: Disciplina de Boli Infecţioase, Facultatea de Medicină, Universitatea de Medicină si Farmacie Gr.T. Popa Iaşi.
authors.forename: Simona Magdalena
authors.initials: SM
authors.lastname: Petrache
authors.forename: Egidia
authors.initials: E
authors.lastname: Miftode
authors.forename: A
authors.initials: A
authors.lastname: Vâţă
authors.forename: Cristina Mirela
authors.initials: CM
authors.lastname: Petrovici
authors.forename: Olivia
authors.initials: O
authors.lastname: Dorneanu
authors.forename: V
authors.initials: V
authors.lastname: Luca
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007121:Immunocompetence; D016867:Immunocompromised Host; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010068:Oxacillin / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D012383:Romania / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D013211:Staphylococcus aureus / Q000302:isolation & purification; D015996:Survival Rate; D017211:Treatment Failure; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D010068:Oxacillin